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ABSTRACT
Alzheimer’s disease (AD) is a devastating form of dementia with 5 million people
suffering from the disease in the United States alone. Thus, there is a need to understand the cause
of AD so that therapeutics can be developed to treat it. The greatest risk factor for AD is the APOE
gene, which encodes the apolipoprotein E protein. Three predominant APOE alleles exist humans,
which give rise to three isoforms, called apoE2, E3, and E4. Individuals with apoE4 are ten times
more likely to develop AD. In contrast, the apoE2 isoform has a neuroprotective effect and is
associated with a 2-fold lower risk of developing AD. A growing body of evidence has
demonstrated that apoE plays a major role in AD and cognitive aging in an isoform-specific
manner, through either contributing to or counteracting AD pathogenesis. Our lab is interested in
studying the molecular mechanisms of apoE in AD, but we first needed to establish a system to
produce apoE protein in mammalian cells. Here, I present the culmination of the work I conducted
in the Adams Lab establishing a system to evaluate apoE isoform-specific effects in mammalian
cells, focusing on the establishment of the 293 FreeStyle Expression system, a serum-free, highdensity HEK cell culture system, to generate recombinant apoE in mammalian cells. From the
generation of apoE expression constructs to the quantification of secreted apoE protein levels, this
project establishes the tools necessary to study apoE in the context of AD in mammalian cell
culture.
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INTRODUCTION
Dementia is the 7th leading cause of death worldwide [1]. Alzheimer’s disease (AD) is the
most common form of dementia, accounting for 60-80% of all cases [2]. Over 5 million Americans
are living with AD and the number is predicted to triple by 2060 [3]. Currently, no effective
therapeutics exist to treat or prevent AD and the cause of the disease is still not well understood.
AD is an especially difficult disease to treat because the disease progression is slow and insidious.
Pathophysiological changes in the brain begin years, if not decades, before the presentation of
cognitive decline [4]. Despite the fact that it was characterized over a century ago, it wasn’t until
the development of recent technology that scientists have been able to investigate the molecular
basis of AD [5]. Since these advancements, research in neuroscience has erupted, and we are
beginning to understand what is happening to the brains of AD patients at a cellular and molecular
level.
AD was first characterized by Dr. Alois Alzheimer (1894-1915), after whom the disease is
named [6]. Alzheimer was a renowned German physician known for his work in neurosyphilis and
vascular dementia [7]. While working at the Frankfurt mental hospital, Alzheimer was presented
with Auguste Deter, a 51-year old woman experiencing memory impairment, mania, insomnia,
and agitation [8]. Alzheimer oversaw Deter’s care and studied her symptoms for several years, and
after her death, conducted an autopsy on her brain. It was here that he first characterized three
distinct abnormalities in Deter’s brain that are now identified as the hallmark features of AD [6].
The first striking observation made by Alzheimer when studying Deter’s brain was profound brain
atrophy. We now know this atrophy to be the result of neurodegeneration (i.e., death of neurons).
Neurons control and execute virtually all aspects of human behavior, including those affected by
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AD

(memory,

motor

function,

language,

emotional regulation) [6]. Alzheimer also
identified two hallmarks at the microscopic level,
now

known

as

amyloid

plaques

and

neurofibrillary tangles.
Neurofibrillary tangles form from the
deposition of hyperphosphorylated tau protein.
Tau is a microtubule-associated protein that is
especially abundant in neurons, where it plays a
central role in the dynamic assembly and
stabilization of microtubule bundles in axons [9].
Microtubules

are

one

of

the

principal

components of the cytoskeletal system where

Figure 1. Neurofibrillary tangle formation and
neurodegeneration. Tau dissociates from
disintegrating microtubules and forms insoluble
oligomers, which aggregate into neurofibrillary
tangles. Created with Biorender.com

they provide structural support and serve as tracks for motor proteins to transport cargo through
the cell. Synapses are especially reliant on cellular trafficking, so impairment to microtubules and
microtubule-associated proteins often lead to synaptic degeneration [10]. In healthy cells, tau
binding to microtubules is regulated by phosphorylation of the microtubule-binding domain of tau,
which dissociates tau from the microtubule during cytoskeletal reassembly [9]. However, in
diseased brains, tau can become hyperphosphorylated, causing it to aggregate into large
neurofibrillary tangles (NFTs) in the cell bodies of neuronal cells, which leads to cell death [11]
(Figure 1). This hyperphosphorylated tau is capable of propagating, or “seeding”, to other cells in
a prion-like manner [12]. Hyperphosphorylated tau spreads in a highly specific manner through
the brain as the disease progresses and has been characterized as a series of distinct stages, known
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as Braak stages [11]. Braak staging is associated with severity of AD symptoms and has shown
recent applications in monitoring disease severity in living humans through PET imaging [13].
Amyloid plaques occur as a result of amyloid-β (Aβ) accumulation. Aβ is produced from
the cleavage of amyloid precursor protein (APP) (Figure 2). While the function of APP itself is
not well understood, the mechanism of enzymatic cleavage by β-secretase and 𝛾-secretase is well
characterized, as well as the oligomerization and accumulation of Aβ in the extracellular space in
the brain, referred to as the parenchyma [14]. Aβ deposition is one of the earliest pathological
mechanisms observed in pre-clinical AD [15], and the development of clinical symptoms is
believed to be due to the deficient brain clearance of the peptide [16] leading to the development
of the amyloid cascade hypothesis of AD [17]. This hypothesis is supported by the fact that
mutations in APP and 1 and -2, the catalytic subunits of 𝛾-secretase, are sufficient to cause earlyonset autosomal dominant AD, also known as familial AD (FAD) [18]. However, this hypothesis
is becoming increasingly controversial as new evidence surfaces. For example, individuals can
present with substantial amyloid burdens without any indications of accompanying cognitive
decline [19, 20]. Additionally, therapies targeting Aβ have generally not been effective, suggesting
that the pathological mechanism of AD is much more complicated than Aβ accumulation [21].

Figure 2. β-Amyloidogenic cleavage of APP by β-secretase and 𝛾-secretase. Aβ is formed from two
cleavage events of APP, resulting in a 40-42 amino acid peptide highly prone to oligomerization.
Created with Biorender.com.
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The APOE gene, which encodes the apolipoprotein EapoE protein, is the strongest known
risk factor for AD [22, 23]. ApoE belongs
to a family of lipoproteins (Figure 3),
which

are

secreted

by

cells

and

incorporated in a complex ball of lipids, or
fats, that function to carry lipids to
growing or damaged neurons [24]. The
APOE gene exists in the population as
three alleles that encode three protein
Figure 3. Apoliprotein E (apoE) in lipoprotein

variants (or, isoforms)--apoE2, apoE3,

complex. The apoE gene encodes the apoE protein,
which is secreted from cells and incorporated into a

and apoE4--that are each 299 amino acids

complex of lipids and other proteins known as a

in length. The apoE isoforms are identical

lipoprotein complex. Created with Biorender.com

with the exception of two amino acids at
positions 112 and 158. ApoE2 has the amino acid cysteine at both positions, apoE3 has cysteine
at 112 and arginine at 158, and apoE4 has arginine at both positions (Figure 4). Importantly,
individuals who inherit the apoE4 isoform are 10 times more likely to develop AD with an age of
onset 10 years younger compared to individuals with apoE3 (the most common isoform). In
contrast, the apoE2 isoform has a neuroprotective effect and is associated with a 2-fold lower risk
of developing AD [23].

Figure 4. Linear schematic depiction of apoE protein. The apoE protein is 299 amino acids in length.
The isoforms differ in positions 112 and 158.
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A growing body of evidence has demonstrated that apoE plays a major role in AD and
cognitive aging in an isoform-specific manner, through either contributing to or counteracting to
AD pathogenesis [25]. A recent case study reported the identification of a rare mutation in apoE3
(R136S), known as apoE Christchurch, which protected an individual with a PSEN1 FAD mutation
from cognitive decline well into her 70s [26]. Similarly, a rare mutation in apoE3 (V236E), known
as apoE Jacksonville, was found to reduce Aβ oligomerization by preventing apoE selfoligomerization [27]. The mechanisms of apoE in AD pathogenesis are so impactful that a new
hypothesis – the apoE cascade hypothesis – is now being entertained as a promising therapeutic
target for AD [28].
I began my research at Bridgewater State University with Dr. Ken Adams in the summer
of 2019 and spent the first 8 months studying the little-known transcriptional coregulator NAB2.
Dr. Adams spent time working with Dr. Bradley Hyman at Massachusetts General Hospital during
his sabbatical in the fall of 2019 and brought back with him a new motivation to start studying AD
in our lab. Eager to start contributing to a cause in research that truly matters, I scrambled to write
a research proposal to study apoE isoform-specific effects on neurite outgrowth in PC12 cells with
the Adrian Tinsley Program Summer Research grant. PC12 cells have long been a popular choice
in studying neuronal mechanisms in cell culture, as treatment with nerve growth factor will trigger
a cascade of cellular events promoting differentiation into a phenotype comparable to sympathetic
neurons [29] (Figure 5). As a continuation of the work I conducted in the spring 2020 semester
establishing conditions to evaluate neurite outgrowth in PC12 cells, I planned to transfect PC12
cells with apoE2, apoE3, or apoE4 and determine if apoE affects neuritogenesis in PC12 cells.
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Figure 5. PC12 cells undergo neuritogenesis in response to nerve growth factor (NGF). Before
treatment with NGF, C12 cells exhibit a rounded morphology (left). When treated with 100 ng/mL
NGF, PC12 cells undergo neuritogenesis to produce long extensions, termed neurites (right).

I was thrilled to be rewarded the Adrian Tinsley Program Summer Research grant in March
of 2020 and immediately began working to establish the tools necessary to complete my project.
However, within a week of receiving apoE expression constructs from the Hyman Lab, the COVID
pandemic had consumed our lab, and I joined scientists around the world in the long, frustrating
wait for lab access. Once conditions were safe enough to conduct research while practicing social
distancing, I was able to finally begin my project. Little did I know that the project I had so
ambitiously proposed in 2020 would present its own unexpected obstacles.

Here, I present the culmination of the work I conducted in the Adams Lab establishing a
system to evaluate apoE isoform-specific effects in mammalian cells, focusing on the
establishment of the 293 FreeStyle Expression system, a serum-free, high-density HEK cell culture
system, to generate recombinant apoE in mammalian cells.
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MATERIALS & METHODS
Molecular cloning
ApoE2, E3, and E4 cDNAs were subcloned from pCMV4-apoE2, E3, and E4 plasmid constructs
(provided from Dr. Bradley T. Hyman, Massachusetts General Hospital) into pcDNA3 plasmid
vector (provided by Dr. Geoffrey M. Cooper, Boston University). Each plasmid was subjected to
double digest in a 50 µl reaction containing 1 µg of plasmid DNA, 20 units of XbaI (New England
Biolabs), 20 units of KpnI (New England Biolabs) and 5 µl of 10X NEBuffer r2.1 (New England
Biolabs). The reactions were mixed and incubated at 37°C for 4 hours. 10 µl of 6X gel loading dye
(New England Biolabs) were added per reaction before electrophoresis through 1% agarose gels
containing ethidium bromide. Gels were visualized over a UV gel dock and bands containing the
desired DNA fragments (apoE2, E3, and E4 inserts and linearized pcDNA3) were excised with a
razor blade. DNA was extracted from each agarose gel slab using the QIAquick Gel Extraction kit
(Qiagen) according to the manufacturer's instructions. In the final step, the DNA fragments were
eluted in 30 µl of nuclease-free ultrapure water (Ambion).
Ligation reactions were conducted using T4 DNA ligase (New England Biolabs). In brief, 20
µl reactions were prepared containing 2 µl of 10X T4 DNA ligase buffer, 800 units of T4 DNA
ligase, and the maximum amount of apoE2, or E3, or E4 insert + pcDNA3 vector to acquire a 3:1
molecular ratio. To calculate 3:1 ratios, concentrations for each DNA fragment were estimated by
assuming 100% recovery during the gel extraction procedure because the actual concentrations
were too low to accurately quantify by spectrophotometry. The reactions were mixed and
incubated at room temperature for approximately 18 hours.
One Shot TOP10 chemically competent E. coli (Thermo Fisher Scientific) were transformed
with each ligation reaction by heat shock. In brief, 5 µl of ligation reaction was added to a vial of
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One Shot TOP10 E. coli and then incubated on ice for 10 minutes with gentle swirling once every
2 minutes. The cells were then subjected to heat shock by incubating in a 42°C water bath for 30
seconds and then incubated on ice for 2 minutes. 500 µl of SOC medium (Thermo Fisher
Scientific) were added to each transformation before incubation at 37°C in a shaker at 250 rpm for
1 hour. The transformations were then distributed evenly onto two agar plates supplemented with
100 µg/ml ampicillin, which were incubated at 37°C for approximately 18 hours to isolate colonies
containing recombinant clones of pcDNA3-apoE2, E3, or E4.
For each ligation reaction transformation (pcDNA3 + apoE2, E3, or E4), several clones were
screened to identify true recombinant plasmids. In brief, for each clone, 6 ml of Luria's Broth (LB)
supplemented with 100 µg/ml of ampicillin were inoculated with a bacterial colony and incubated
for 8–12 hours at 37°C in a shaker at 250–300 rpm. Cells were then collected by centrifugation at
4000 rpm for 15 minutes at 4°C and subjected to plasmid mini prep using QIAprep Spin Miniprep
Kit (Qiagen) according to the manufacturer's instructions. In the final step, plasmid DNA was
eluted in 30 µl of nuclease-free water and quantified using a NanoDrop One spectrophotometer
(Thermo Fisher Scientific).
Each clone recovered by mini prep was subjected to double restriction digest with XbaI + KpnI
followed by agarose gel electrophoresis, as described above, to confirm the presence of an apoE
insert + pcDNA3 vector. Clones with insert and vector of expected sizes were then subjected to
Sanger sequencing (Eurofins Genomics) using T7 and SP6 primers, for which pcDNA3 has
priming sites located upstream and downstream, respectively, of its multiple cloning site. The
sequencing results were then examined to confirm the presence of the full apoE allele—E2, E3, or
E4—sequence. One clone for each apoE isoform was then selected for plasmid maxi prep, for
which transformed E. coli were expanded 200 ml of LB supplemented with 100 µg/ml ampicillin
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for 18 hours. Plasmid maxi prep was then conducted using the QIAGEN Plasmid Maxi Kit
(Qiagen) and final plasmid concentrations determined with a NanoDrop One spectrophotometer.
Site-directed mutagenesis
Site-directed mutagenesis (SDM) was conducted to mutate arginine-158 to cysteine in pcDNA3apoE3 using the QuickChange XL Site-Directed Mutagenesis Kit (Agilent Technologies)
according to the manufacturer's instructions. Mutagenic primers were generated with a melting
temperature (Tm) of 78-83°C using the following equation:
Tm = 81.5 + 0.41(% GC) – (675/N) - % mismatch
for which N equals the primer length, % GC and % mismatch were both included as whole
numbers. The following primers were designed and ordered as custom primers from Integrated
DNA Technologies:
(sense) 5’-GCC GAT GAC CTG CAG AAG TGC CTG GCA GTG TAC C-3’
(antisense) 5’-G GTA CAC TGC CAG GCT CTT CTG CAG GTC ATC GGC-3’

Once received, the primers were suspended to in Tris-EDTA (TE), pH 8.0 buffer at 1 mg/ml
concentration and stored at -20°C.
SDM reactions were prepared with a total volume of 50 µl and containing 5 µl of 10x reaction
buffer (provided with the kit), 10 ng of the appropriate pcDNA3-apoE plasmid, 125 ng of each
mutagenic primer, 1 µl of dNTP mix (provided with the kit), 3 µl of QuickSolution (DMSO,
provided with the kit), and 1 µl of Pfu Turbo DNA polymerase (2.5 units). The reactions were
mixed and then subjected to polymerase chain reaction (PCR) in a thermal cycler with the
following parameters:
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Step

Cycles

Temperature

Time

1

1

95°C

1 minute

95°C

50 seconds

60°C

50 seconds

68°C

7 minutes*

68°C

7 minutes

2
3

18

4
5

1

*The step 4 time was based on the manufacturer's recommendation for 1 minute/kilobase of
plasmid. The pcDNA3-apoE plasmids are approximately 6500 base pairs, thus step 4 was carried
out for 7 minutes.
Following PCR, 10 units of DpnI restriction endonuclease were added to each reaction to digest,
which was mixed and incubated at 37°C for 1 hour to digest the parental DNA.
To recover mutant clones, XL-10 Gold Ultracompetent E. coli (Agilent Technologies) were
transformed with the DpnI-treated PCR product. To do so, XL-10 Gold cells were thawed
gentley on ice and 45 µl of the cell suspension was transferred to a pre-chilled 14-ml BD Falcon
polypropylene round-bottom tube. 2 µl of b-mercaptoethanol mix (provided with the E. coli)
were added to the cells, which were then mixed and incubated on ice for 10 minutes with gentle
swirling every 2 minutes. 2 µl of the DpnI-treated PCR product were added and the suspension
was gently mixed by swirling and incubated on ice for 30 minutes. The mixture was then
subjected to heat shock at 42°C for 30 seconds and placed back on ice for 2 minutes. 500 µl of
pre-warmed NZY+ broth was added to each transformation and the suspensions were incubated at
37°C for 1 hour in a shaker at 250 rpm. Each transformation was then distributed evenly between
two agar plates supplemented with 100 µg/ml ampicillin, which were incubated at 37°C for 18–
20 hours to grow and isolate transformed colonies with mutant clones. For each SDM reaction,
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several colonies were then grown, subjected plasmid mini prep using QIAprep Spin Miniprep Kit
according to the manufacturer's instructions. In the final step, plasmid DNA was eluted in 30 µl
of nuclease-free water and quantified using a NanoDrop One spectrophotometer.
Recovered clones were subjected to Sanger sequencing via Eurofins Genomics using two
primers, T7 (5'-TAATACGACTCACTATAGGG-3') and a custom primer named ApoEF1 (5'TTTGGGATTACCTGCGCTGG-3'). As previously noted, pcDNA3 vector has a T7 priming site
upstream of its multiple cloning site. The ApoEF1 primer was designed to anneal within the
apoE cDNA insert, 216 base pairs upstream of the codon for cysteine/arginine-112, 354 bp
upstream of the codon for cysteine/arginine-158, and 783 bp from the stop codon. These two
primers yielded complete coverage of the entire apoE insert sequence, enabling identification of
clones containing the intended mutation and lacking unintended mutations, deletions, or
insertions. Positive clones were selected for plasmid maxi prep, for which transformed E. coli
were expanded 200 ml of LB supplemented with 100 µg/ml ampicillin for 18 hours. Plasmid
maxi prep was then conducted using the QIAGEN Plasmid Maxi Kit and final plasmid
concentrations determined with a NanoDrop One spectrophotometer.
PC12 and HEK cell culture and plasmid transfection
PC12 cells were grown in Dulbecco’s modification of Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (FBS), 5% horse serum (HS), and penicillin and streptomycin (P/S)
at 37ºC incubator and 10% CO2. HEK 293 cells were maintained in DMEM supplemented with
10% FBS and P/S also at 37ºC incubator and 10% CO2. Transfections of both cell lines were
conducted using TransIT-LT1 transfection reaction (Mirus). One day before transfection, 1-1.5 x
106 cells were plated on 60 mm tissue culture dishes in 4 ml of growth medium. The following
day, for each culture, transfection mixtures were prepared consisting of 500 µl of serum-free
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DMEM, 2 µg of plasmid DNA, and 10 µl of TransIT-LT1, which were incubated 15-30 minutes
at room temperature before applying to the appropriate cell culture in a drop-wise manner. The
transfections were then incubated at 37°C at 10% CO2 for 18-24 hours before the medium was
replaced with either full-serum growth medium or low-serum medium, as discussed in the Results
section.
FreeStyle 239-F cell culture and transfection
FreeStyle™ 293-F cells (Invitrogen R790-07) were maintained following recommendations from
the manufacturer. Cells were incubated in a 37°C incubator containing a humidified atmosphere
of 8% CO2 on an orbital shaker platform rotating at 125 rpm in disposable, sterile, Erlenmeyer
flasks with vented caps. For cell line maintenance, 293-F cells were grown in FreeStyle 293
Expression Medium (Invitrogen 12338-026) supplemented with P/S. Cells were subcultured every
3-5 days once the cell density reached 1-3 x 106 cells/ml. To count cells, a small aliquot of cells
was vortexed briefly and combined with PBS at a 1:1 ratio. The PBS/cell suspension mixture was
combined with Trypan Blue Solution (Gibco 15250061) at a 1:1 ratio and counted using a
hemocytometer. Cells were then seeded at a density of 3-5 x 105 cells/ml in fresh expression
medium. Transfections were conducted using 293fection transfection reagent (Invitrogen, 12347019). For each transfection culture, 30 µg of plasmid DNA were diluted in 1 ml of either FreeStyle
293 Expression Medium or Opti-MEM I Reduced-Serum Medium (Invitrogen 31985-062) and 60
µl of 293fectin were diluted in a separate 1 ml of either FreeStyle 293 Expression Medium or OptiMEM I Reduced-Serum Medium. The mixtures were incubated separately for 5 minutes and then
combined and incubated for an additional 30 minutes before applied to 293-F cells at 1 x 106
cells/ml in 30 ml total volume of FreeStyle 293 Expression Medium.
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Collecting and concentrating conditioned medium from 293-F transfections
To collect conditioned medium for time-course experiments, 400 μl of cell suspension were
centrifuged at 7,900 x g in a table-top microcentrifuge for 5 minutes. Supernatant or cell pellets
were combined at a 1:1 ratio with 2x Laemmli buffer (Bio-Rad 15250061) and boiled for 5
minutes. For concentrating conditioned medium, 20-30 ml of cell suspensions were centrifuged at
200 x g for 5 minutes. 15 ml of conditioned medium were applied to Amico Ultra-15 Centrifugal
Filter Units with a 10 kDa molecular weight cutoff (Millipore, UFC901024). The filter units were
centrifuged 5000 x g at 4ºC 10 min several times until the volume was reduced to approximately
1 ml. 100 μl of concentrated medium was combined with 100 μl of 2x Laemmli buffer and boiled
for 5 minutes.
SDS-PAGE, general protein staining, and Western blot
20 μl of conditioned medium samples and cell lysates were electrophoresed through 10% SDSpolyacrylamide gels alongside E. coli-derived recombinant apoE (produced by Dr. Adams) to use
as standard. Gels were then either incubated in InstantBlue Coomassie Protein Stain (Abcam
ab119211) for 15 minutes or transferred to nitrocellulose membrane. Membranes were blocked in
5% nonfat dried milk in tris buffered saline (TBS) + 0.2% Tween-20 (blocking buffer) for 1 hour
at room temperature. Blocking buffer was then removed and replaced with primary antibody
diluted in blocking buffer to detect apoE (Novus, NPBI-31123, 1:5,000 dilution) or β-actin (Sigma,
A5441, 1:20,000 dilution) to incubate for 1 hour at room temperature. Membranes were washed
three times for 15 minutes in TBS + 0.2% Tween-20 at room temperature. Secondary antibody
(goat anti-rabbit HRP-conjugate, Bio-Rad, 172–1019, 1:3000 dilution for apoE Western blots; goat
anti-mouse HRP-conjugate, Bio-Rad, 170–6516, 1:20,000 dilution for b-actin Western blots) was
diluted in fresh blocking buffer and placed on the membranes to incubate for 1 hour at room

17

temperature. Membranes were washed three times for 15 minutes in TBS + 0.2% Tween-20 at
room temperature and imaged with C-Digit Blot Scanner (LI-COR) by chemiluminescence
(Western Lightning Plus ECL, Enhanced Chemiluminescence Substrate, Perkin Elmer,
NEL105001).
Quantification of apoE protein levels
For quantification of conditioned medium samples, standards were prepared from recombinant
apoE produced in E. coli diluted in 2X Laemmli sample buffer. 15 μl of standards and conditioned
medium samples were subjected to SDS-PAGE through a 10% SDS-polyacrylamide gels. Gels
were then incubated in Instant Blue Coomassie protein stain for 15 minutes and scanned with a
standard desktop scanner. Images were then analyzed with ImageJ (NIH) Gel Analyzer. Images
were converted to 8-bit and a rectangular selection about 1/3 the width of the protein band of the
first lane was drawn and marked as the first lane. This selection was then dragged to the next lane
and marked as “next lane” until all lanes had been selected (Figure 6A). The lanes were then plotted
to produce a profile for each lane and the area under the peak was measured (Figure 6B).

Figure 6. Representative screen displays of Gel Analyzer ImageJ software.

Data for each gel were imported into GraphPad Prism 9 software for linear regression analysis.
ApoE standard concentrations (in μg) were plotted against area under the peak (in AU).
Concentration of apoE in conditioned medium samples were interpolated from the linear
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regression. Given that each lane of the gel contains 7.5 μl of conditioned medium (15 μl per lane,
1:1 Laemmli to conditioned medium), interpolated values can be converted to μg/mL
concentrations as follows:

µg apoE (interpolated) ∗ 1000
= apoE (ng/µl) = apoE (µg/mL)
7.5 µl
For quantification of concentrated apoE fractions, μg/mL concentrations were calculated as above
and multiplied by the associated dilution factor. These results were averaged to approximate the
concentration of the concentrated preps.
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RESULTS
In order to express human apoE in mammalian cells, pCMV4-apoE2, E3, and E4 constructs were
acquired from Dr. Bradley T. Hyman (Massachusetts General Hospital). However, generating
sufficient supplies of the pCMV4-apoE constructs by plasmid maxi prep proved challenging for
reasons that are unclear. KpnI and XbaI restriction enzyme sites were identified flanking the apoE
cDNAs in the pCMV4 vector and also present in the multiple cloning site in the pcDNA3 vector
in the needed orientation. (Figure
7). pcDNA3 vector and pCMV4apoE2, apoE3, and apoE4 plasmids
were subjected to double digest
with KpnI and XbaI restriction
enzymes. Digest reactions were
electrophoresed through a 1%
agarose gel and visualized on UV
transilluminator, which confirmed
digested fragments of the sizes
expected

for

the

linearized

pcDNA3 vector and apoE cDNA
inserts (Figure 8A). Linearized
Figure 7. Subcloning of apoE cDNA from pCMV4 into

pcDNA3 vector and apoE cDNAs

pcDNA3

were excised from the gel, purified,

vector

schematic.

Schematic

showing

the

subcloning protocol for digesting pCMV4-ApoE and pcDNA3
vector with KpnI and XbaI restriction enzymes to generate an
apoE cDNA insert compatible with the pcDNA3 vector .

and combined in ligation reactions.
E. coli were transformed with the
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A

pcDNA3 Vector

pCMV4-ApoE
ApoE2

ApoE3

ApoE4

6 kb

1 kb

B

pcDNA3
Vector

pcDNA3

pcDNA3-ApoE3

Vector

pcDNA3-ApoE2

pcDNA3-ApoE4

Figure 8. Subcloning of apoE cDNA from pCMV4 into pcDNA3 vector. (A)Separation of apoE cDNAs
from pCMV4 via agarose gel electrophoresis. Linearized pcDNA3 vector and apoE cDNAs were excised
from the gel and purified with Qiagen Gel Extraction Kit. (B) Confirmation of pcDNA3-ApoE ligations.
Clones resulting from pcDNA3-apoE ligations were subjected to agarose gel electrophoresis to confirm
insertion of apoE cDNAs.

ligation reactions to recover recombinant clones, which were subjected to double digest with KpnI
and XbaI and screened through agarose gel electrophoresis, confirming the successful insertion of
apoE cDNAs (Figure 8B). . E. coli were transformed with the ligation reactions to recover
recombinant clones, which were subjected to double digest with KpnI and XbaI and screened
through agarose gel electrophoresis, confirming the successful insertion of apoE cDNAs (Figure
8B). The clones were also screened by Sanger sequencing to confirm the presence of the correct
apoE isoform insert—E2, E3, or E4. Unexpectedly, the Sanger sequencing results indicated a 20
bp deletion was upstream of the apoE insert in the pcDNA3-apoE2 clones (Figure 9). Although
the deletion was not within the apoE2 coding sequence, we were concerned that the deletion could
impact expression levels of apoE2 versus apoE3 and apoE4 from their respective constructs,
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Figure 9. Identification of deletion upstream of apoE2 cDNA. Sequencing of pcDNA3-apoE2
ligations revealed a 20 bp deletion upstream of apoE2 cDNA present in all clones, highlighted in red.

perhaps complicating interpretation of experimental
results. T Thus, pcDNA3-apoE2 was generated from
pcDNA3-apoE3 through site-directed mutagenesis to
introduce C112R. pcDNA3-apoE2, pcDNA3-apoE3,
and pcDNA3-apoE4 sequences were then finally
confirmed through Sanger sequencing (Figure 10).
As previously discussed, the original goal of
my thesis project was to evaluate apoE isoformspecific effects on neuritogenesis, using PC12 cells
as a model system. PC12 cells respond to nerve
growth factor (NGF) by differentiating into neuronallike cells, but in order to elicit a robust differentiation
response, the cells must be maintained in low-serum

Figure 10. Sequence confirmation of

medium [31]. However, exposure to reduced growth

pcDNA3-apoE constructs. Chromatograms
for amino acid positions 112 and 158 in

factors also inhibits protein synthesis [31] so we

pcDNA3-apoE2 (Cys / Cys), apoE3 (Cys /

needed to confirm that PC12 cells would continue to

Arg), and apoE4 (Arg / Arg).
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express apoE in the absence of growth factors. PC12 cells were plated in collagen-coated 6-well
plates and transfected with pcDNA3 vector or pcDNA3-apoE3 in full-serum medium. Cells were
maintained in full-serum medium for 24 hours, after which medium was replaced with full-serum
medium or low-serum medium. Cells in low-serum medium were treated with NGF 24 hours after
the medium change. Conditioned medium was collected over the course of five days in Laemmli
buffer and subjected to SDS-PAGE and Western blot to detect apoE protein. ApoE was not
detected in the conditioned medium of the transfected cells grown in low-serum medium compared
to cells kept in full-serum medium. (Figure 11). Unfortunately, these data indicated that our
experimental system to evaluate isoform-specific effects of apoE on neuritogenesis was not
technically feasible.
Days Post
Transfection:

Full-serum medium

Low-serum medium

ApoE

Figure 11. ApoE expression in PC12 cells. PC12 cells were transfected with pcDNA3apoE3 and grown in either full-serum medium or Low-serum media. Conditioned medium
samples were subjected to SDS-PAGE and Western blot to detect apoE.
In December of 2020, I gave a journal club presentation on a recent publication from Dr.
Thomas C. Südof’s lab [32], in which they demonstrated apoE isoform-specific activation of the
ERK/MAP kinase pathway in neurons upon treatment with conditioned medium from HEK-293
cells transfected with apoE expression constructs. They reported that apoE in the conditioned
medium was usually 50-80x more concentrated than their desired treatment dose (10 μg/mL). They
also reported a simple method for quantification of apoE using a recombinant protein standard,
which can be used to generate a densitometric standard curve to interpolate the concentrations of
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apoE in the conditioned medium [33]. If HEK-293 cells could produce such a high concentration
of apoE, the medium could be diluted enough to significantly reduce the concentration of serum
proteins, thus providing a source of recombinant apoE that we could introduce to PC12 cells
without introducing large amounts of serum proteins. To evaluate this approach as an alternative
to PC12 transfections, HEK293 cells were transfected with pcDNA3-apoE3 and conditioned
medium was collected over a course of six days. Huang et al. (2017) conducted densitometry on
Coomassie-stained SDS-PAGE gels run with conditioned medium from HEK-293 cells.
Coomassie true-blue staining of SDS-PAGE gels run with conditioned medium collected from our
HEK-293 cells revealed a strikingly abundant amount of serum proteins in the medium, which
made discerning the apoE protein from the rest of the proteins in the medium impractical (Figure
12A). Therefore, Western blot was conducted on the conditioned medium samples alongside E.
coli-derived recombinant apoE standards (Figure 12B). The apoE concentration in the medium
was significantly below the concentration used in the standards, but we approximated that the
concentration of apoE in the conditioned medium was about 25% of the lowest concentration used
in the standard (10 ng/lane). If we were to treat PC12 cells with the same concentration of apoE as
Huang et al. (2017) used in their experiments when treating neurons, we would need to treat the
cells with 10 μg/mL apoE.
Given that each lane of the gel contains 7.5 μl of conditioned medium (15 μl per lane, 1:1
Laemmli to conditioned medium), the amount of conditioned medium required to treat a 60 mm
tissue culture plate with PC12 cells grown in 4 mL of medium could be approximated as follows:
1000 ng
7.5 µl
40 µg apoE +
. +
. = 30 mL of conditioned media per plate
1 µg
10 ng
Since this treatment dose would be physically impossible to administer, we were forced to
reconsider our methodology.
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A
500 ng
Rec. ApoE

Days Post Transfection
5
(4.5 x 10 cells)

B
E.coli ApoE Standard (ng)

Days Post Transfection
6
(1.5 x 10 cells)

Days Post Transfection
6
(1.5 x 10 cells)

Figure 12. ApoE expression in HEK-293 cells. HEK-293 cells were transfected with pcDNA3apoE3 and monitored over six days. To ensure cells remained viable through the six-day
timecourse, HEK-293 cells were plated at two different densities. (A) Coomassie staining of
HEK-293 conditioned medium. (B) Western blot with E. coli apoE standards probing for apoE.
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Huang et al. (2019) referred to a specialized line of HEK-293 cells, FreeStyle 293-F cells,
which are cultured in suspension in serum-free medium. Based on the abundance of serum proteins
present in medium conditioned by standard HEK-293 cell, we considered the use of FreeStyle 293F cells as a source of mammalian-derived recombinant apoE protein. Thus, 293-F cells were
acquired and transfected with pcDNA3-apoE3 or pcDNA3 vector and monitored over the course
of four days. At each time point, a 500 µl fraction of each culture was collected and subjectd to
centrifugation at 7,900 x g in a table-top microcentrifuge for 5 minutes. The resulting cell pellet
and supernatant—the conditioned medium—were then separated. The cell pellet was suspended
in 200 µl of Laemmli buffer, the conditioned medium was combined 1:1 with Laemmli buffer,
and the samples were boiled for 5–10 minutes to lyse the cell pellet and denature the proteins in
all samples. Equal volumes of each sample were then subjected to SDS-PAGE and Western blot
to detect apoE and β-actin (Figure 13A). As expected, apoE was detected in the conditioned
medium of pcDNA3-apoE3–transfected cells and accumulated through the course of 4 days,
whereas apoE was not detected in conditioned medium 4 days after transfection with with pcDNA3
empty vector. ApoE3 was also detected in the lysates of pcDNA3-apoE3–transfected cells,
although its levels were largely constant throughout 4 days, reflecting the fact that newly
synthesized apoE3 was continuously secreted, yielding a steady-state level of apoE3 in the cells
over time. We also failed to detect β-actin in the conditioned medium samples, confirming that the
cells were separated from the conditioned medium successfully. Total protein staining with
Coomassie of SDS-PAGE gel with E. coli apoE standards revealed that apoE was the predominant
protein in the conditioned medium (Figure 13B), a shocking contrast from the total protein-staining
of the full-serum HEK-293 medium (see Figure 12A). 293-F cells were then transfected with
pcDNA3-apoE2, apoE3, or apoE4 and conditioned medium was collected over five days for SDSPAGE and Western blot analysis (Figure 13B). ApoE2, apoE3, and apoE4 accumulated in a timedependent manner, peaking at 4 days post transfection.
In order to produce as much apoE in the conditioned media as possible, we needed to
determine the optimum transfection conditions for protein expression. Cell viability of HEK-293-

26

F cells cultured in FreeStyle Expression Medium supplemented with penicillin + streptomycin
(P/S) was stable during cell line maintenance, but once transfected with pcDNA3 vector, crude
analysis by Trypan Blue staining suggested that cell viability decreased significantly. Thus, to
quantify whether P/S affects cell viability during transfections, we then assessed whether culturing
cells in the absence of P/S would rescue cell viability during transfection. Cells transfected with
pcDNA3 in the presence of P/S exhibited a 20% decrease in viability, while cells grown in the
absence of P/S were more than 95% viable following transfection (Figure 14A). These data
indicated that, while 293-F cells appear to withstand the presence of P/S in their medium under
standard culturing conditions, the inclusion of P/S during transfection causes undesired cytotoxic
effects. Not only would this cytotoxicity likely reduce yields of apoE, it could also result in the
release of cellular factors from dying cells that could complicate the effects of apoE treatments.
Thus, these data provided strong incentive to exclude P/S from the cultures during our transfection
experiments.
The manufacturer of 293-F cells (Invitrogen) recommends that transfection mixtures be
prepared in Opti-MEM low-serum medium for optimal transfection efficiency, so we also
compared transfection efficiency of cells transfected with pGFP using FreeStyle Expression
Medium or Opti-MEM low-serum medium in the transfection mixtures. Transfection efficiency
increased from 67% to 77% in the presence of Opti-MEM (Figure 14B), so we decided to continue
using Opti-MEM for future transfections.
A significant challenge in working with recombinant apoE is quantifying its concentration,
as ELISA often yields unreliable data (unpublished communications with Dr. Bradley T. Hyman’s
laboratory, Massachusetts General Hospital) and serum proteins can obscure other protein
quantification methods such as BCA and Bradford assays. Huang et al. (2017) used Coomassie
staining of conditioned media from 293-F cells alongside a series of protein standards to produce
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A

B

Figure 13. Characterization of apoE expression in FreeStyle cells. (A) 293F cells were transfected
with pcDNA3 vector or pcDNA3-ApoE3. Conditioned medium and cell lysates were collected over four
days and subjected to SDS-PAGE and Western blot alongside 100 ng His-ApoE purified from E. coli,
CM=Vector Day 3 conditioned medium, CL=Vector Day 3 cell lysates; (B) 293F cells were transfected
with apoE2, apoE3, or apoE4 and conditioned medium was collected over five days. Conditioned
medium samples were subjected to SDS-PAGE alongside 100 ng His-ApoE purified from E. coli. Gels
were then stained with Coomassie protein stain or subjected to Western blot.
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Figure 14. Determination of transfection efficiency. (A) 293F cells were transfected with pcDNA3 in the
presence or absence of P/S and monitored over the course of three days. Cell counts were collected with a
hemocytometer using Trypan Blue as a viability marker (B) 293F cells were transfected with pGFP and
subjected to flow cytometry. Transfection efficiency was determined as a measure of FITC absorption by
positively transfected cells expressing pGFP.

a densitometric standard curve from which the concentration of the conditioned media can be
approximated. To test this strategy, conditioned media produced through apoE2, apoE3, and apoE4
transfections were subjected to SDS-PAGE alongside apoE produced from E coli to use as
standards, which had been successfully quantified by BCA assay. Gels were stained with
Coomassie Instant Blue stain and scanned using a desktop office scanner. Linear regression of the
concentration of apoE in the protein standards plotted against the area under the peak (AU)
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Figure 15. Quantification of apoE2, apoE3, and apoE4 protein levels. (A) 293F cells were transfected
with (A) pcDNA3-ApoE2, (B) pcDNA3-ApoE3, and (C) pcDNA3-ApoE4. Conditioned medium was
collected over the course of five days and subjected to SDS-PAGE alongside a His-ApoE protein standard. A
densitometric standard curve was generated for each gel and used to interpolate the concentration of apoE in
the conditioned medium samples. (D) Violin plot for E. coli apoE standard curves from apoE2, apoE3, and
apoE4 quantification gels.
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collected through ImageJ GelAnalyzer produced a remarkably well-fit regression lines (r2 = 0.986,
r2 = 0.999, r2 = 0.980) (Figure 15A-C). AU for the protein standards was generally consistent
between gels, but became more variable at higher concentrations (Figure 15D). Interpolation of
apoE concentrations from the densitometric standard curve revealed surprisingly high
concentrations of apoE, reaching 200-300 μg/mL four days post-transfection.
Protein is generally more stable during storage at higher concentrations and generating
concentrated sources of apoE is beneficial for conducting experimental treatments. Thus,
experiments were conducted to concentrate apoE secreted from HEK 293-F cells. To do so, HEK
293-F cells were transfected with pcDNA3-apoE2, apoE3, apoE4, or pcDNA3 vector and
conditioned media was collected after 5 days. Conditioned medium was concentrated using 10
kDa molecular weight cutoff centrifugal filter units and then subjected to SDS-PAGE. ApoE was
not detected in the flowthrough fractions, but concentration of the medium revealed the presence
of extraneous proteins undetected in the unconcentrated medium (Figure 16A). Quantification of
the concentrated medium demonstrated that the concentrations were 1-3 mg/mL, indicating a 510-fold increase from unconcentrated medium (Figure 16B).
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Figure 16. Concentrating FreeStyle apoE. Conditioned medium from FreeStyle cells transfected with
pcDNA3-ApoE2, ApoE3, apoE4 or vector was collected on D5 and concentrated with Millipore filter
units with a 10 kDa molecular weight cutoff. (A)Undiluted fractions of unconcentrated (UC),
concentrated (C), or flowthrough (FT) from the filter units. (B) Concentrated apoE was diluted and
subjected to SDS-PAGE alongside His-ApoE standard. (C) Standard curve generated from densitometric
analysis of E. coli apoE standard. (D) ApoE was then quantified as described previously. The mean
concentration interpolated from each dilution was calculated.
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DISCUSSION
From the generation of apoE expression constructs to the quantification of secreted apoE
protein levels, this project establishes the tools necessary to study apoE in the context of AD in
mammalian cell culture. Conditioned medium produced by HEK 293-F cells contains minimal
protein aside from secreted recombinant apoE, which is highly concentrated and easily
quantifiable. Additionally, we observed a distinct banding pattern in recombinant apoE secreted
by HEK-293-F cells that was not observed in apoE produced from E. coli indicative of posttranslational modifications (see Figure 15 and Figure 16). Post-translational modifications have an
established role in regulating protein function, and apoE has been reported to be subject to
methylation [34], S-nitrosylation [35], glycosylation [36], sialyation [37], as well as other
modifications, often in an isoform-specific manner [38]. Evidence of post-translational
modifications in apoE produced from 293-F cells provides increased confidence in the potential
applications of the FreeStyle System. Recent studies in our lab (Durant, unpublished) show
promising results in the use of apoE produced from 293-F cells in thermal shift assays, and
experiments treating PC12 and N2A cells with apoE conditioned medium are ongoing. The
groundwork has been laid, and I am thrilled to begin using this system for my Master’s thesis at
Bridgewater State University, where I will (finally) begin studying apoE isoform-specific effects
in mammalian cell culture.
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